Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지

The Role of Immunotherapy in Treatment of Tuberculosis

결핵 치료에서 면역요법의 역할

  • Yim, Jae-Joon (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute, Seoul National University College of Medicine) ;
  • Han, Sung Koo (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute, Seoul National University College of Medicine)
  • 임재준 (서울대학교 의과대학 내과학교실 및 폐연구소) ;
  • 한성구 (서울대학교 의과대학 내과학교실 및 폐연구소)
  • Published : 2005.05.30
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. WHO. Stop TB: 2001 annual report. 2002
  2. Dye C, Espinal MA, Watt CJ, Mbiaga C,Williams BG. Worldwide incidence of multidrug: resistant tuber-culosis. J Infect Dis 2002;185:1197-202 https://doi.org/10.1086/339818
  3. Mukherjee JS, Rich ML, Socci AR, Joseph JK, Viru FA, Shin SS, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 2004;363:474-81 https://doi.org/10.1016/S0140-6736(04)15496-2
  4. Smith KA. Interleukin-2: inception, impact, and implications. Science 1988;240:1169-76 https://doi.org/10.1126/science.3131876
  5. Kuziel WA, Greene WC. Interleukin-2 and the IL-2 receptor: new insights into structure and function. J Invest Dermatol 1990;94:27S-32S https://doi.org/10.1111/1523-1747.ep12875017
  6. Johnson BJ, Ress SR, Willcox P, Pati BP, Lorgat F, Stead P, et al. Clinical and immune responses of tuberculosis patients treated with low-dose IL-2 and multidrug therapy. Cytokines Mol Ther 1995;1:185-96
  7. Johnson BJ, Bekker LG, Rickman R, Brown S, Lesser M, Ress S, et al. rhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placebo. Tuber Lung Dis 1997;78:195-203 https://doi.org/10.1016/S0962-8479(97)90026-5
  8. Belardelli F. Role of interferons and other cytokines in the regulation of the immune response. APMIS 1995;103:161-79. https://doi.org/10.1111/j.1699-0463.1995.tb01092.x
  9. Romagnani S. Induction of TH1 and TH2 responses:a key role for the 'natural' immune response? Immunol Today 1992;13:379-81 https://doi.org/10.1016/0167-5699(92)90083-J
  10. Brinkmann V, Geiger T, Alkan S, Heusser CH. Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells. J Exp Med 1993;178:1655-63 https://doi.org/10.1084/jem.178.5.1655
  11. Giosue S, Casarini M, Alemanno L, Galluccio G, Mattia P, Pedicelli G, et al. Effects of aerosolized interferon-alpha in patients with pulmonary tuber-culosis. Am J Respir Crit Care Med 1998;158:1156-62 https://doi.org/10.1164/ajrccm.158.4.9803065
  12. Palmero D, Eiguchi K, Rendo P, Castro Zorrilla L, Abbate E, Gonzalez Montaner LJ. Phase II trial of recombinant interferon-alpha2b in patients with advanced intractable multidrug-resistant pulmonary tuberculosis: long-term follow-up. Int J Tuberc Lung Dis 1999;3:214-8
  13. Giosue S, Casarini M, Ameglio F, Zangrilli P, Palla M, Altieri AM, et al. Aerosolized interferon-alpha treatment in patients with multi-drug-resistant pulmonary tuberculosis. Eur Cytokine Netw 2000;11:99-104
  14. Tomura M, Maruo S, Mu J, Zhou XY, Ahn HJ, Hamaoka T, et al. Differential capacities of CD4+, CD8+, and CD4-CD8- T cell subsets to express IL-18 receptor and produce IFN-gamma in response to IL-18. J Immunol 1998;160:3759-65
  15. Mountford AP, Coulson PS, Cheever AW, Sher A, Wilson RA, Wynn TA. Interleukin-12 can directly induce T-helper 1 responses in interferon-gamma(IFN- gamma) receptor-deficient mice, but requires IFN-gamma signalling to downregulate T-helper 2 responses. Immunology 1999;97:588-94 https://doi.org/10.1046/j.1365-2567.1999.00832.x
  16. Murray HW. Current and future clinical applications of interferon-gamma in host antimicrobial defense. Intensive Care Med 1996;22(Suppl 4):S456-61 https://doi.org/10.1007/BF01712166
  17. Darnell JE Jr. Studies of IFN-induced transcriptional activation uncover the Jak-Stat pathway. J Interferon Cytokine Res 1998;18:549-54 https://doi.org/10.1089/jir.1998.18.549
  18. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993;178:2249-54 https://doi.org/10.1084/jem.178.6.2249
  19. Dorman SE, Holland SM. Mutation in the signaltransducing chain of the interferon-gamma receptor and susceptibility to mycobacterial infection. J Clin Invest 1998;101:2364-9 https://doi.org/10.1172/JCI2901
  20. Holland SM, Eisenstein EM, Kuhns DB, Turner ML, Fleisher TA, Strober W, et al. Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma: a preliminary report. N Engl J Med 1994;330:1348-55 https://doi.org/10.1056/NEJM199405123301904
  21. Condos R, Rom WN, Schluger NW. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet 1997;349:1513-5 https://doi.org/10.1016/S0140-6736(96)12273-X
  22. Suarez-Mendez R, Garcia-Garcia I, Fernandez-Olivera N, Valdes-Quintana M, Milanes-Mirelles MT, Carbonell D, et al. Adjuvant interferon gamma in patients with drug-resistant pulmonary tuberculosis: a pilot study. BMC Infect Dis 2004;4:44
  23. Koh WJ, Kwon OJ, Suh GY, Chung MP, Kim H, Lee NY, et al. Six-month therapy with aerosolized interferon-gamma for refractory multidrug-resistant pulmonary tuberculosis. J Korean Med Sci 2004;19:167-71 https://doi.org/10.3346/jkms.2004.19.2.167
  24. Kim EK, Shim TS, Lee JY, Oh YM, Lim CM, Lee SD, et al. The adjuvant effect of subcutaneous interferon-gamma in the treatment of refractory multidrugresistant pulmonary tuberculosis. Tuberc Respir Dis 2004;57:226-33 https://doi.org/10.4046/trd.2004.57.3.226
  25. Park SK, Chen DS, Lee IH, Lee DH. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma subcutaneous injection. Tuber Lung Dis 2004;55:S9
  26. Stanford JL, Rook GA, Bahr GM, Dowlati Y, Ganapati R, Ghazi Saidi K, et al. Mycobacterium vaccae in immunoprophylaxis and immunotherapy of leprosy and tuberculosis. Vaccine 1990;8:525-30 https://doi.org/10.1016/0264-410X(90)90002-4
  27. Stanford JL, Bahr GM, Rook GA, Shaaban MA, Chugh TD, Gabriel M, et al. Immunotherapy with Mycobacterium vaccae as an adjunct to chemotherapy in the treatment of pulmonary tuberculosis. Tubercle 1990;71:87-93 https://doi.org/10.1016/0041-3879(90)90002-P
  28. Onyebujoh PC, Abdulmumini T, Robinson S, Rook GA, Stanford JL. Immunotherapy with Mycobacterium vaccae as an addition to chemotherapy for the treatment of pulmonary tuberculosis under difficult conditions in Africa. Respir Med 1995;89:199-207 https://doi.org/10.1016/0954-6111(95)90248-1
  29. Durban Immunotherapy Trial Group. Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis: a randomised controlled trial. Lancet 1999;354:116-9 https://doi.org/10.1016/S0140-6736(98)10448-8
  30. Mwinga A, Nunn A, Ngwira B, Chintu C, Warndorff D, Fine P, et al. Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard anti-tuberculosis treatment in HIV-infected adults with pulmonary tuberculosis: a randomised placebo-controlled trial. Lancet 2002;360:1050-5 https://doi.org/10.1016/S0140-6736(02)11141-X
  31. Johnson JL, Kamya RM, Okwera A, Loughlin AM, Nyole S, Hom DL, et al. Randomized controlled trial of Mycobacterium vaccae immunotherapy in non-human immunodeficiency virus-infected ugandan adults with newly diagnosed pulmonary tuberculosis. J Infect Dis 2000;181:1304-12 https://doi.org/10.1086/315393
  32. Wang W, Jin G, Ye Y, Xia X, Wang A, Zhuang Y, et al. A clinical study on vaccine of Mycobacterium vaccae in treating pulmonary tuberculosis. Zhonghua Jie He He Hu Xi Za Zhi 1999;22:108-10
  33. Luo Y. The immunotherapeutic effect of Mycobacterium vaccae vaccine on initially treated pulmonary tuberculosis. Zhonghua Jie He He Hu Xi Za Zhi 2001;24:43-7
  34. Luo Y, Lu S, Guo S. Immunotherapeutic effect of Mycobacterium vaccae on multi-drug resistant pulmonary tuberculosis. Zhonghua Jie He He Hu Xi Za Zhi 2000;23:85-8